Abstract:Introduction
Ductal Eccrine carcinoma (DEC) is a rare primary cutaneous tumor that exhibits both squamous and adnexal ductal differentiation. Due to its rarity in clinical practice we present as case of DEC and a literature review on the latest management of this rare disease.
Case presentation
We report a case 41 years old female presented with lesion on the scalp and sternal mass, increasing in size with itchiness and erythematous for 6 months duration. Further CECT s… Show more
“…9,29,30 Although eccrine adenocarcinoma and spiradenocarcinoma are very rare and limited data exist regarding their natural history and behavior, case reports have identified infiltrative growth patterns and perineural invasion in some of these tumors. [31][32][33] Positive surgical margins have several important clinical consequences. First, in cases where achieving a negative surgical margin is deemed necessary to treatment, positive margins can lead to the need for multiple excisions, leading to increases in cost of treatment, complexity of reconstruction, and burden to patients.…”
Section: Discussionmentioning
confidence: 99%
“…9,29,30 Although eccrine adenocarcinoma and spiradenocarcinoma are very rare and limited data exist regarding their natural history and behavior, case reports have identified infiltrative growth patterns and perineural invasion in some of these tumors. 31–33…”
BACKGROUND
It is recommended to excise adnexal neoplasms with standard local excision or Mohs micrographic surgery (MMS), although many occur on high-risk sites such as the head and neck (H&N) and exhibit subclinical extension. Minimal evidence exists on the efficacy of standard excisions for these tumors.
OBJECTIVE
To evaluate the rate of positive surgical margins after standard excision of adnexal tumors.
METHODS
Retrospective cohort study of cutaneous adnexal malignancies from the National Cancer Database diagnosed from 2004 to 2019.
RESULTS
The authors identified a total of 4,402 cases treated with standard excision. Tumors on the H&N were approximately twice as likely as those on the trunk and extremities (T&E) to be excised with positive margins (odds ratio 2.146, p < .001), with the highest estimated rate for eccrine adenocarcinoma (12.1%, SE: 2.3%). The subtype with the highest positive margin rate on the T&E was microcystic adnexal carcinoma (8.0%, SE: 2.9). Positive margins were associated with poorer overall survival on multivariable survival analysis (hazard ratio 1.299, p = .015).
CONCLUSION
The authors present subtype- and site-specific positive margin rates for adnexal tumors treated with standard excision, which suggest that tumors on the H&N and some T&E subtypes, should be considered for MMS.
“…9,29,30 Although eccrine adenocarcinoma and spiradenocarcinoma are very rare and limited data exist regarding their natural history and behavior, case reports have identified infiltrative growth patterns and perineural invasion in some of these tumors. [31][32][33] Positive surgical margins have several important clinical consequences. First, in cases where achieving a negative surgical margin is deemed necessary to treatment, positive margins can lead to the need for multiple excisions, leading to increases in cost of treatment, complexity of reconstruction, and burden to patients.…”
Section: Discussionmentioning
confidence: 99%
“…9,29,30 Although eccrine adenocarcinoma and spiradenocarcinoma are very rare and limited data exist regarding their natural history and behavior, case reports have identified infiltrative growth patterns and perineural invasion in some of these tumors. 31–33…”
BACKGROUND
It is recommended to excise adnexal neoplasms with standard local excision or Mohs micrographic surgery (MMS), although many occur on high-risk sites such as the head and neck (H&N) and exhibit subclinical extension. Minimal evidence exists on the efficacy of standard excisions for these tumors.
OBJECTIVE
To evaluate the rate of positive surgical margins after standard excision of adnexal tumors.
METHODS
Retrospective cohort study of cutaneous adnexal malignancies from the National Cancer Database diagnosed from 2004 to 2019.
RESULTS
The authors identified a total of 4,402 cases treated with standard excision. Tumors on the H&N were approximately twice as likely as those on the trunk and extremities (T&E) to be excised with positive margins (odds ratio 2.146, p < .001), with the highest estimated rate for eccrine adenocarcinoma (12.1%, SE: 2.3%). The subtype with the highest positive margin rate on the T&E was microcystic adnexal carcinoma (8.0%, SE: 2.9). Positive margins were associated with poorer overall survival on multivariable survival analysis (hazard ratio 1.299, p = .015).
CONCLUSION
The authors present subtype- and site-specific positive margin rates for adnexal tumors treated with standard excision, which suggest that tumors on the H&N and some T&E subtypes, should be considered for MMS.
“…Eccrine carcinomas represent a subset of MCATs originating from eccrine glands, the most widely distributed sweat gland type. Eccrine carcinomas account for less than 0.01% of all cutaneous malignancies [1]. While the classification of eccrine carcinomas is complex and the nomenclature is often inconsistent, well-described subtypes include eccrine porocarcinoma, eccrine spiradenocarcinoma, and syringoid eccrine carcinoma [2].…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, diagnosis is based primarily on morphological assessment. However, the diversity and rarity of eccrine carcinomas makes correct morphological classification challenging [1, 5]. In DEA, the appearance of marked ductal proliferation mimics metastatic adenocarcinoma from non-cutaneous sites such as the breast, further complicating the differential diagnosis [3].…”
Eccrine carcinoma, a subtype of which is ductal eccrine adenocarcinoma (DEA), is a rare cutaneous malignancy. For metastatic eccrine carcinoma, there are very limited data to guide treatment. Conventional chemotherapy is of limited benefit and there is only a small body of evidence for the use of immunotherapy in non-DEA eccrine carcinomas. We report the first case of metastatic DEA treated with a multimodality approach including surgery, radiotherapy, and immunotherapy, with an excellent prolonged response to pembrolizumab, and provide a review of the literature on pathological and management aspects for this rare tumour subtype. A 60-year-old male with a history of pT1N0M0 left scalp DEA, managed 2 years prior with excision and adjuvant radiotherapy, represented with a symptomatic right pontine metastasis. Imaging demonstrated intracranial, pulmonary, and hilar disease; biopsy of the cranial and lung lesions showed metastatic adenocarcinoma, morphologically similar to the previously resected scalp DEA. The patient was treated with stereotactic resections of his pontine metastases and adjuvant cranial radiotherapy, then commenced on immunotherapy with pembrolizumab. The patient has completed 21 months of pembrolizumab with a significant radiological response of the pulmonary and hilar disease and nil evidence of intracranial recurrence or further metastases. In this case report, we provide the first evidence of efficacy of immunotherapy in metastatic DEA, demonstrating an excellent and prolonged response of metastatic DEA to pembrolizumab. Further research is required to better establish the role of immunotherapy within the management protocol for this uncommon but aggressive tumour subtype.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.